The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.
Led by a group of 10 biopharmaceutical firms, the project will use Olink's proteomic technology to look at participants' plasma levels of roughly 1,500 proteins.
The genome-wide association study, conducted by a DeCode Genetics-led team, further uncovered variants influencing the perception of licorice and cinnamon smells.
SomaLogic will analyze more than 40,000 samples, including from Amgen clinical trials, using its SomaScan platform, which measures up to 5,000 proteins.
The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.
The team also found that the proportion of infected people didn't change substantially during the screening period, consistent with beneficial containment.
